AA
48
-12
STZ
54
-3
BAC
53
3
SIG
52
3
SLB
55
2
MLM
57
6
VRSN
53
-4
CMG
72
5
GE
67
2
NVDA
56
-4
DG
6
2
ES
34
3
TSCO
49
5
EQT
57
-2
FITB
63
3
URI
65
5
AXP
71
2
IR
66
3
GPC
40
3
GOOG
50
-3
AA
48
-12
STZ
54
-3
BAC
53
3
SIG
52
3
SLB
55
2
MLM
57
6
VRSN
53
-4
CMG
72
5
GE
67
2
NVDA
56
-4
DG
6
2
ES
34
3
TSCO
49
5
EQT
57
-2
FITB
63
3
URI
65
5
AXP
71
2
IR
66
3
GPC
40
3
GOOG
50
-3
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
45

PTGX
Protagonist Therapeutics

Last Price:
46.45
Seasonality Move:
11.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Protagonist Therapeutics Price Quote

$46.45
-0.01 (11.52%)
(Updated: November 23, 2024 at 5:50 AM ET)

Protagonist Therapeutics Key Stats

Sell
45
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$42.40 - $47.50
52-week range:
$16.80 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.86
P/B ratio:
5.21%
Volume:
1.3M
Avg. volume:
679.9K
1-year change:
176.05%
Market cap:
$2.8B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 56.38
Upside from Last Price: 21.34%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    109.4M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders